Cerebrovascular events

1. SGLT2 inhibitors lower the risk of cerebrovascular events in humans (HR 0.36, 95% CI 0.18–0.74).

   “Patients receiving SGLT2 inhibitors also experienced a lower incidence of cerebrovascular events (hazard ratio 0.36, 95% CI 0.18–0.74, p =0.002).”

   Humansin patients with atrial fibrillation without diabetes

   SGLT2 Inhibitors in Atrial Fibrillation Patients without Diabetes: A Propensity-Matched Analysis of Mortality and Cerebrovascular Outcomes

   AHA Scientific Sessions 2025 abstract·3 Nov 2025

More on SGLT2 inhibitors

1. Down syndrome raises the risk of cerebrovascular events in humans (RR 2.70, 95% CI 2.08, 3.53).

   “DS was associated with a greater risk of incident cerebrovascular events (Risk Ratio, RR 2.70, 95% CI 2.08, 3.53)”

   Humans

   Risk of Major Cardiovascular Events in People with Down Syndrome

   PloS one·30 Sep 2015

More on Down syndrome